BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 14, 2003
View Archived Issues
Indevus Prices $60M In Notes For Overactive Bladder Therapy
Read More
Clot-Busting Drugs Urged By Cardiology College Denied Many Heart-Attack Patients By Doctors
Read More
Proposed Public Offering From Vicuron Highlights Funding Rush
Read More
Other News To Note
Read More
Appointments And Announcements
Read More
CV Therapeutics Regains Full Ranexa Rights From Innovex
Promising Phase III data plus a respectable bank account prompted CV Therapeutics Inc. to renegotiate with partner Innovex Inc. for a return of all rights associated with the chronic angina candidate Ranexa. (BioWorld Today)
Read More